Trade HOOKIPA Pharma Inc. - HOOK CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
Spread | 0.0132 | ||||||||
Long position overnight fee
Long position overnight fee
Go to platform | -0.026179% | ||||||||
Short position overnight fee
Short position overnight fee
Go to platform | 0.003957% | ||||||||
Overnight fee time | 21:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | USD | ||||||||
Margin | 5% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
*Information provided by Capital.com
HOOKIPA Pharma Inc ESG Risk Ratings
‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.
Prev. Close* | 0.7161 |
Open* | 0.7282 |
1-Year Change* | 0.4% |
Day's Range* | 0.7232 - 0.7837 |
52 wk Range | 0.41-2.05 |
Average Volume (10 days) | 678.72K |
Average Volume (3 months) | 51.56M |
Market Cap | 55.90M |
P/E Ratio | -100.00K |
Shares Outstanding | 83.95M |
Revenue | 20.55M |
EPS | -0.99 |
Dividend (Yield %) | N/A |
Beta | 0.98 |
Next Earnings Date | Mar 13, 2024 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Apr 22, 2024 | 0.7161 | -0.0152 | -2.08% | 0.7313 | 0.7382 | 0.6982 |
Apr 19, 2024 | 0.7302 | -0.0180 | -2.41% | 0.7482 | 0.7582 | 0.7106 |
Apr 18, 2024 | 0.7582 | -0.0020 | -0.26% | 0.7602 | 0.7882 | 0.7482 |
Apr 17, 2024 | 0.7607 | -0.0475 | -5.88% | 0.8082 | 0.8082 | 0.7392 |
Apr 16, 2024 | 0.7851 | 0.0368 | 4.92% | 0.7483 | 0.8051 | 0.7282 |
Apr 15, 2024 | 0.7385 | -0.0297 | -3.87% | 0.7682 | 0.8382 | 0.7282 |
Apr 12, 2024 | 0.7845 | -0.0237 | -2.93% | 0.8082 | 0.8282 | 0.7102 |
Apr 11, 2024 | 0.8034 | 0.0252 | 3.24% | 0.7782 | 0.8267 | 0.7782 |
Apr 10, 2024 | 0.8182 | -0.0257 | -3.05% | 0.8439 | 0.8439 | 0.7982 |
Apr 9, 2024 | 0.8282 | -0.0300 | -3.50% | 0.8582 | 0.8892 | 0.8183 |
Apr 8, 2024 | 0.8382 | 0.0700 | 9.11% | 0.7682 | 0.8631 | 0.7382 |
Apr 5, 2024 | 0.7381 | 0.0077 | 1.05% | 0.7304 | 0.7437 | 0.7004 |
Apr 4, 2024 | 0.7434 | -0.0148 | -1.95% | 0.7582 | 0.7762 | 0.7382 |
Apr 3, 2024 | 0.7672 | 0.0390 | 5.36% | 0.7282 | 0.7757 | 0.7282 |
Apr 2, 2024 | 0.7482 | 0.0300 | 4.18% | 0.7182 | 0.7572 | 0.6992 |
Apr 1, 2024 | 0.7096 | 0.0014 | 0.20% | 0.7082 | 0.7282 | 0.7082 |
Mar 28, 2024 | 0.7102 | -0.0090 | -1.25% | 0.7192 | 0.7333 | 0.7082 |
Mar 27, 2024 | 0.7182 | 0.0200 | 2.86% | 0.6982 | 0.7252 | 0.6982 |
Mar 26, 2024 | 0.7162 | 0.0130 | 1.85% | 0.7032 | 0.7182 | 0.6982 |
Mar 25, 2024 | 0.6982 | -0.0250 | -3.46% | 0.7232 | 0.7282 | 0.6930 |
HOOKIPA Pharma Inc. Events
Time (UTC) | Country | Event |
---|---|---|
Thursday, April 25, 2024 | ||
Time (UTC) 12:00 | Country US
| Event HOOKIPA Pharma Inc HB-200 Phase 2/3 Clinical Trial Update HOOKIPA Pharma Inc HB-200 Phase 2/3 Clinical Trial UpdateForecast -Previous - |
Thursday, May 9, 2024 | ||
Time (UTC) 12:30 | Country US
| Event Q1 2024 HOOKIPA Pharma Inc Earnings Release Q1 2024 HOOKIPA Pharma Inc Earnings ReleaseForecast -Previous - |
Friday, June 7, 2024 | ||
Time (UTC) 14:00 | Country US
| Event HOOKIPA Pharma Inc Annual Shareholders Meeting HOOKIPA Pharma Inc Annual Shareholders MeetingForecast -Previous - |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total revenue | 14.249 | 18.448 | 19.584 | 11.942 | 7.629 |
Revenue | 14.249 | 18.448 | 19.584 | 11.942 | 7.629 |
Total Operating Expense | 87.404 | 100.122 | 72.869 | 63.027 | 28.809 |
Selling/General/Admin. Expenses, Total | 20.189 | 19.172 | 19.715 | 17.809 | 6.844 |
Research & Development | 67.126 | 80.518 | 52.738 | 44.854 | 21.965 |
Operating Income | -73.155 | -81.674 | -53.285 | -51.085 | -21.18 |
Interest Income (Expense), Net Non-Operating | 0.946 | -0.871 | -0.386 | 0.71 | -0.778 |
Other, Net | 7.524 | 6.881 | 9.589 | 7.338 | 5.745 |
Net Income Before Taxes | -64.685 | -75.664 | -44.082 | -43.037 | -16.213 |
Net Income After Taxes | -64.915 | -75.665 | -44.082 | -43.037 | -16.237 |
Net Income Before Extra. Items | -64.915 | -75.665 | -44.082 | -43.037 | -16.237 |
Net Income | -64.915 | -75.665 | -44.082 | -43.037 | -16.237 |
Income Available to Common Excl. Extra. Items | -64.915 | -75.665 | -44.082 | -43.037 | -16.237 |
Income Available to Common Incl. Extra. Items | -64.915 | -75.665 | -44.082 | -43.037 | -16.237 |
Diluted Net Income | -64.915 | -75.665 | -44.082 | -43.037 | -16.237 |
Diluted Weighted Average Shares | 65.513 | 32.8336 | 26.0391 | 25.5661 | 25.4085 |
Diluted EPS Excluding Extraordinary Items | -0.99087 | -2.3045 | -1.69292 | -1.68336 | -0.63904 |
Dividends per Share - Common Stock Primary Issue | 0 | ||||
Diluted Normalized EPS | -0.99087 | -2.3045 | -1.69292 | -1.68336 | -0.63904 |
Depreciation / Amortization | 0.089 | 0.432 | 0.416 | 0.364 |
Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
---|---|---|---|---|---|
Total revenue | 2.679 | 3.176 | 7.828 | 2.23 | 2.746 |
Revenue | 2.679 | 3.176 | 7.828 | 2.23 | 2.746 |
Total Operating Expense | 24.151 | 25.833 | 21.416 | 23.223 | 21.173 |
Selling/General/Admin. Expenses, Total | 4.445 | 4.902 | 3.824 | 4.937 | 5.026 |
Research & Development | 19.706 | 20.931 | 17.592 | 18.286 | 16.147 |
Operating Income | -21.472 | -22.657 | -13.588 | -20.993 | -18.427 |
Interest Income (Expense), Net Non-Operating | 1.214 | 1.049 | 0.801 | 0.43 | -0.049 |
Other, Net | 2.242 | 2.133 | 0.705 | 2.283 | 2.121 |
Net Income Before Taxes | -18.016 | -19.475 | -12.082 | -18.28 | -16.355 |
Net Income After Taxes | -18.016 | -19.68 | -12.311 | -18.28 | -16.356 |
Net Income Before Extra. Items | -18.016 | -19.68 | -12.311 | -18.28 | -16.356 |
Net Income | -18.016 | -19.68 | -12.311 | -18.28 | -16.356 |
Income Available to Common Excl. Extra. Items | -18.016 | -19.68 | -12.311 | -18.28 | -16.356 |
Income Available to Common Incl. Extra. Items | -18.016 | -19.68 | -12.311 | -18.28 | -16.356 |
Diluted Net Income | -18.016 | -19.68 | -12.311 | -18.28 | -16.356 |
Diluted Weighted Average Shares | 82.7053 | 54.7208 | 65.513 | 54.7337 | 54.698 |
Diluted EPS Excluding Extraordinary Items | -0.21783 | -0.35964 | -0.18792 | -0.33398 | -0.29902 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
Diluted Normalized EPS | -0.21783 | -0.35964 | -0.18792 | -0.33398 | -0.29902 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total Current Assets | 147.196 | 102.135 | 171.504 | 128.017 | 62.311 |
Cash and Short Term Investments | 112.488 | 65.921 | 142.743 | 113.151 | 48.58 |
Cash & Equivalents | 112.488 | 65.921 | 142.743 | 113.151 | 48.58 |
Total Receivables, Net | 22.012 | 21.166 | 20.657 | 9.727 | 4.919 |
Accounts Receivable - Trade, Net | 6.533 | 6.895 | 5.542 | 1.537 | 4.919 |
Prepaid Expenses | 12.159 | 14.482 | 8.104 | 5.139 | 8.812 |
Total Assets | 170.454 | 126.045 | 187.817 | 143.745 | 68.251 |
Property/Plant/Equipment, Total - Net | 21.976 | 22.115 | 13.969 | 14.603 | 4.337 |
Property/Plant/Equipment, Total - Gross | 29.755 | 28.481 | 19.066 | 18.049 | 6.403 |
Accumulated Depreciation, Total | -7.779 | -6.366 | -5.097 | -3.446 | -2.066 |
Other Long Term Assets, Total | 1.282 | 1.795 | 2.344 | 1.125 | 1.603 |
Total Current Liabilities | 35.632 | 27.654 | 21.143 | 14.755 | 14.695 |
Accounts Payable | 5.488 | 8.762 | 8.009 | 0.944 | 3.656 |
Accrued Expenses | 12.069 | 9.598 | 7.138 | 5.262 | 4.42 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 1.224 | 0 |
Other Current Liabilities, Total | 16.481 | 6.481 | 5.841 | 7.166 | 6.619 |
Total Liabilities | 67.937 | 36.453 | 31.694 | 25.846 | 23.852 |
Total Long Term Debt | 0.911 | 2.219 | 4.795 | 3.862 | 4.392 |
Long Term Debt | 0.911 | 2.219 | 4.537 | 3.495 | 4.392 |
Other Liabilities, Total | 31.394 | 6.58 | 5.756 | 7.229 | 4.765 |
Total Equity | 102.517 | 89.592 | 156.123 | 117.899 | 44.399 |
Redeemable Preferred Stock | 0 | 104.774 | |||
Common Stock | 0.005 | 0.003 | 0.003 | 0.003 | 0 |
Additional Paid-In Capital | 397.349 | 317.135 | 309.288 | 225.568 | 3.327 |
Retained Earnings (Accumulated Deficit) | -287.681 | -222.766 | -147.101 | -103.019 | -59.982 |
Other Equity, Total | -7.156 | -4.78 | -6.067 | -4.653 | -3.72 |
Total Liabilities & Shareholders’ Equity | 170.454 | 126.045 | 187.817 | 143.745 | 68.251 |
Total Common Shares Outstanding | 54.7167 | 31.2032 | 29.7684 | 25.5661 | 25.4085 |
Current Port. of LT Debt/Capital Leases | 1.594 | 2.813 | 0.155 | 0.159 | |
Capital Lease Obligations | 0 | 0 | 0.258 | 0.367 | |
Preferred Stock - Non Redeemable, Net | 0 | ||||
Other Current Assets, Total | 0.537 | 0.566 |
Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | |
---|---|---|---|---|---|
Total Current Assets | 139.471 | 168.143 | 139.913 | 147.196 | 129.611 |
Cash and Short Term Investments | 107.676 | 135.587 | 109.6 | 112.488 | 99.776 |
Cash & Equivalents | 107.676 | 135.587 | 109.6 | 112.488 | 99.776 |
Total Receivables, Net | 23.05 | 20.461 | 18.463 | 22.012 | 12.045 |
Accounts Receivable - Trade, Net | 0.675 | 0.255 | 0.501 | 6.533 | 0.743 |
Prepaid Expenses | 8.745 | 12.095 | 11.85 | 12.159 | 17.3 |
Total Assets | 164.01 | 191.11 | 163.088 | 170.454 | 151.526 |
Property/Plant/Equipment, Total - Net | 23.029 | 21.54 | 21.661 | 21.976 | 20.553 |
Other Long Term Assets, Total | 1.51 | 1.427 | 1.514 | 1.282 | 1.362 |
Total Current Liabilities | 40.576 | 46.245 | 44.209 | 35.632 | 26.052 |
Accounts Payable | 8.929 | 11.645 | 7.075 | 5.488 | 7.824 |
Accrued Expenses | 14.054 | 13.215 | 15.012 | 12.069 | 8.757 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 1.026 | 1.012 | 2.067 | 1.594 | 1.393 |
Other Current Liabilities, Total | 16.567 | 20.373 | 20.055 | 16.481 | 8.078 |
Total Liabilities | 68.959 | 78.78 | 79.609 | 67.937 | 38.178 |
Total Long Term Debt | 0 | 0 | 0 | 0.911 | 2.4 |
Long Term Debt | 0 | 0 | 0 | 0.911 | 0.8 |
Capital Lease Obligations | 0 | 1.6 | |||
Other Liabilities, Total | 28.383 | 32.535 | 35.4 | 31.394 | 9.726 |
Total Equity | 95.051 | 112.33 | 83.479 | 102.517 | 113.348 |
Preferred Stock - Non Redeemable, Net | 0 | ||||
Common Stock | 0.008 | 0.008 | 0.005 | 0.005 | 0.005 |
Additional Paid-In Capital | 445.512 | 444.941 | 398.008 | 397.349 | 396.348 |
Retained Earnings (Accumulated Deficit) | -344.443 | -325.377 | -307.361 | -287.681 | -275.37 |
Other Equity, Total | -6.026 | -7.242 | -7.173 | -7.156 | -7.635 |
Total Liabilities & Shareholders’ Equity | 164.01 | 191.11 | 163.088 | 170.454 | 151.526 |
Total Common Shares Outstanding | 83.9501 | 83.9501 | 54.7223 | 54.7167 | 54.7167 |
Property/Plant/Equipment, Total - Gross | 32.019 | 30.466 | 30.089 | 29.755 | 27.207 |
Accumulated Depreciation, Total | -8.99 | -8.926 | -8.428 | -7.779 | -6.654 |
Other Current Assets, Total | 0 | 0 | 0 | 0.537 | 0.49 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Net income/Starting Line | -64.915 | -75.665 | -44.082 | -43.037 | -16.237 |
Cash From Operating Activities | -19.997 | -66.016 | -39.339 | -41.731 | -14.998 |
Cash From Operating Activities | 3.602 | 4.64 | 4.15 | 1.443 | 0.64 |
Non-Cash Items | 5.203 | 8.87 | 8.71 | 7.241 | 0.874 |
Cash Taxes Paid | 0.001 | 0.001 | 0 | 0 | 0.024 |
Cash Interest Paid | 0.032 | 0.048 | 0.097 | 0.064 | 0.071 |
Changes in Working Capital | 36.113 | -3.861 | -8.117 | -7.378 | -0.275 |
Cash From Investing Activities | -5.017 | -12.581 | -2.371 | -1.999 | -2.15 |
Capital Expenditures | -5.017 | -12.581 | -2.371 | -1.999 | -2.15 |
Cash From Financing Activities | 72.271 | -0.235 | 73.42 | 109.751 | 6.873 |
Issuance (Retirement) of Stock, Net | 75.316 | 0.203 | 75.063 | 112.03 | 6.864 |
Issuance (Retirement) of Debt, Net | -2.85 | -0.438 | -1.419 | -2.279 | 0.009 |
Foreign Exchange Effects | -0.725 | 2.567 | -2.108 | -1.026 | -2.507 |
Net Change in Cash | 46.532 | -76.265 | 29.602 | 64.995 | -12.782 |
Financing Cash Flow Items | -0.195 | 0 | -0.224 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | -19.68 | -64.915 | -52.604 | -34.324 | -17.968 |
Cash From Operating Activities | -2.848 | -19.997 | -33.134 | -16.626 | 1.733 |
Cash From Operating Activities | 0.921 | 3.602 | 2.698 | 1.938 | 1.078 |
Non-Cash Items | 0.662 | 5.203 | 4.03 | 3.158 | 1.695 |
Cash Taxes Paid | 0 | 0.001 | 0.001 | 0.001 | 0 |
Cash Interest Paid | 0.001 | 0.032 | 0.021 | 0.022 | 0 |
Changes in Working Capital | 15.249 | 36.113 | 12.742 | 12.602 | 16.928 |
Cash From Investing Activities | -0.274 | -5.017 | -4.418 | -3.46 | -1.828 |
Capital Expenditures | -0.274 | -5.017 | -4.418 | -3.46 | -1.828 |
Cash From Financing Activities | -0.735 | 72.271 | 72.467 | 72.34 | 75.293 |
Issuance (Retirement) of Stock, Net | 0.001 | 75.316 | 75.316 | 75.314 | 75.313 |
Issuance (Retirement) of Debt, Net | -0.597 | -2.85 | -2.849 | -2.974 | -0.02 |
Foreign Exchange Effects | 0.434 | -0.725 | -1.151 | -0.307 | -0.307 |
Net Change in Cash | -3.423 | 46.532 | 33.764 | 51.947 | 74.891 |
Financing Cash Flow Items | -0.139 | -0.195 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
HOOKIPA Pharma Inc. Company profile
About Hookipa Pharma Inc
HOOKIPA Pharma Inc. is a clinical-stage biopharmaceutical company. The Company develops immunotherapeutics based on its arenavirus platform that are designed to target and amplify a T cell and immune response to disease. The Company's infectious and oncology product candidates HB-101, HB-201, HB-202 and HB-300. The infectious disease product candidate, HB-101, is in a randomized, double-blinded Phase II clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates, HB-201 and HB-202, are in development for the treatment of human papillomavirus-positive cancers. The Company is developing its self-antigen project in this area, HB-300, as a replicating technology-based product candidate in metastatic, hormone-resistant prostate cancer.
Financial summary
BRIEF: For the nine months ended 30 September 2021, Hookipa Pharma Inc revenues increased 1% to $14.6M. Net loss increased 72% to $54.4M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and development - Balancing val increase of 60% to $58M (expense), Other income and expenses, net decrease from $1.6M (income) to $1.3M (expense).
Industry: | Pharmaceuticals (NEC) |
The Empire State Building
350 Fifth Avenue, Room/Suite 7240
NEW YORK
NEW YORK 10118
US
Income Statement
- Annual
- Quarterly
News
We’re partnering with Newsquawk
Filter out the noise and focus on the news that matters.
08:32, 23 April 2024US Earnings Season: Tesla, Alphabet, Meta Platforms and Microsoft
The first lot of Wall Street’s mega-cap tech companies report in the coming week. We preview what to expect from Tesla, Alphabet, Meta, and Microsoft’s quarterly results.
15:56, 22 April 2024Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported
Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.
07:56, 17 April 2024US Earnings Season : JP Morgan, Citigroup, Wells Fargo
The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.
16:03, 11 April 2024Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues
The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.
09:22, 11 April 2024US CPI Preview: US inflation expected to grind lower amid fears about sticky prices
US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).
15:11, 9 April 2024How escalating geopolitical tensions are impacting oil markets
The bullish momentum in oil prices remains strong as escalating geopolitical tensions raise concerns about supply.
13:34, 4 April 2024People also watch
Still looking for a broker you can trust?
Join the 610,000+ traders worldwide that chose to trade with Capital.com